PMA18: THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES  by Bakst, A et al.
188 Abstracts
were involved in the study, which focused on the French
public mental health care system. Each service was classi-
fied according to the ESMS and data were collected on
service use. The data for each catchment area were aggre-
gated in residential use, structured day activities, continu-
ous out patient care and emergency out patient care, then
a cluster analysis was performed. The ESMS classifica-
tion of the services based on function was compared to
the official French description of services. RESULTS:
Four classes were identified: Class 1 high activity in all
services, class 2 low activity in all services, class 3 low ac-
tivity in continuous ambulatory care, class 4 high activity
in continuous ambulatory care. The ESMS confirmed the
consistency between the French official description of the
services’ missions and the actual activity. 10% of the ser-
vices had at least one additional “non official” function.
The study showed that the ESMS was adapted for use in
France, but it requires expert supervision for large-scale
implementation. CONCLUSIONS: The ESMS proves to
be useful not only in mental health service research, but
can also bring the possibility to adjust for the catchment
area’s service profile in outcomes research.
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AWARe® is an Internet-based database designed to cap-
ture clinical and humanistic outcomes from diabetes
practice settings around the world. The main goal of
AWARe® is to better understand how patients with type
2 diabetes respond to different treatments in a naturalis-
tic environment. OBJECTIVE: To describe an innovative
method of collecting clinical, humanistic and economic
outcomes of patients with type 2 diabetes in a “real
world” practice setting. METHODS: The data collection
methods involve the electronic linkage of clinical infor-
mation and humanistic outcomes of patients with type 2
diabetes. Patients at least 18 years of age who are main-
tained on oral antidiabetic therapy are eligible to partici-
pate in AWARe®. As providers enter patients’ clinical in-
formation into the patient’s electronic medical record, the
data elements of interest are automatically transmitted to
a secure Internet site (Pharmacon EB-HealthTM) where the
data are stored and continuously updated. Data collected
in AWARe® include: demographic information, pre-
scription use, HbA1c, fasting plasma glucose, total cho-
lesterol, triglycerides, LDL, HDL, blood pressure, liver
function tests, the SF-36, and the Diabetes and Treatment
Satisfaction Questionnaire (DTSQ). Every six months,
participants use hand-held devices to complete the elec-
tronic versions of the SF-36 and the DTSQ. The results
from these surveys are instantaneously transmitted via
wireless technology to EB-HealthTM. CONCLUSION:
AWARe® permits immediate retrieval of clinical and hu-
manistic information from an Internet-based registry. In-
formation on the patient’s clinical progress may be con-
tinuously transmitted to EB-HealthTM, allowing researchers,
clinicians and administrators to perform “real time”
analyses of the clinical effectiveness of antidiabetic ther-
apy, as well as to determine its impact on patients’ qual-
ity of life and satisfaction with treatment. As AWARe® is
expanded to sites around the US and throughout the
world, it will provide valuable information on the impact
of the different treatments for type 2 diabetes on patients’
clinical, humanistic and economic outcomes.
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OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is one of the most prevalent of childhood men-
tal disorders, and represents the most common reason
children are referred to mental health providers.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who use large-scale administrative databases to evalu-
ate quality of care for mental disorders and associated
patient outcomes. Purchasers of health care who provide
health services to patients with psychiatric disorders.
The presence of the disorder is associated with substan-
tial health resource utilization and costs. Although evi-
dence-based guidelines for the pharmacologic treatment
of ADHD are widely available, little is known about vari-
ation in provider prescribing practices, patient compli-
ance, and attendant patient health outcomes. This is espe-
cially problematic because psychostimulants, commonly
prescribed for ADHD as a daily regimen, are frequently
taken solely on an “as needed” basis to improve behav-
iors during school hours. We are currently conducting a
program of research using large-scale, national, inte-
grated pharmacy benefits and medical claims databases
to examine the quality of ADHD pharmacologic care, pa-
tient compliance, and associated patient outcomes. The
objectives of this workshop are to discuss the complexi-
